Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to make it easier for licensed pharmacists or physicians to compound and distribute limited quantities of drugs for urgent administration in hospitals or clinical settings when the drug has recently been on the FDA drug shortage list. It establishes conditions for that limited distribution (e.g., prescriber certification that outsourcing-facility product was unavailable, beyond-use dating per United States Pharmacopeia, packaging labels limiting use to urgent administration, timely patient-identifying records, and adverse event reporting to FDA’s MedWatch within 15 days).
Balance of access vs. safety: liberals emphasize stronger safety, oversight, and public reporting; conservatives emphasize preserving flexibility while limiting regulatory expansion.
Relative to its intended legislative type, this bill is a substantive statutory amendment that meaningfully revises compounding and drug‑shortage reporting law with targeted, concrete provisions, but it leaves several implementation and resourcing gaps that reduce precision and enforceability.
The bill amends the Federal Food, Drug, and Cosmetic Act to make it easier for licensed pharmacists or physicians to compound and distribute limited quantities of drugs for urgent administration in hospitals or clinical settings when the drug has recently been on the FDA drug shortage list.
It establishes conditions for that limited distribution (e.g., prescriber certification that outsourcing-facility product was unavailable, beyond-use dating per United States Pharmacopeia, packaging labels limiting use to urgent administration, timely patient-identifying records, and adverse event reporting to FDA’s MedWatch within 15 days).
The bill also expands and clarifies FDA shortage reporting requirements to include surges in demand as well as interruptions or discontinuances (with a 6-month prior notice requirement for planned interruptions where feasible), adjusts timing/window language related to outsourcing facility compounding and shortage criteria, requires annual public updates about bulk drug substance evaluations, and adds a required compounded-drug labeling statement.
On content alone, the bill is a modest, targeted regulatory adjustment addressing a recognized problem (drug shortages) and includes safeguards, which increases prospects for bipartisan support. However, the technical changes implicate FDA authority, patient safety, and commercial interests; those stakeholder frictions and moderate implementation complexity reduce the likelihood relative to purely noncontroversial technical fixes. The absence of explicit funding and the use of documentation and reporting conditions make enactment plausible but not certain.
Relative to its intended legislative type, this bill is a substantive statutory amendment that meaningfully revises compounding and drug‑shortage reporting law with targeted, concrete provisions, but it leaves several implementation and resourcing gaps that reduce precision and enforceability.
Balance of access vs. safety: liberals emphasize stronger safety, oversight, and public reporting; conservatives emphasize preserving flexibility while limiting regulatory expansion.
These are examples from the analysis, not a ranked list of the most-affected groups.
Balance of access vs. safety: liberals emphasize stronger safety, oversight, and public reporting; conservatives emphasize preserving flexibility while limiting regulatory expansion.
A mainstream progressive would likely welcome the bill’s stated goal of improving patient access to needed medications during shortages and its enhancements to FDA reporting.
They would be supportive insofar as the bill helps hospitals obtain urgently needed drugs that are otherwise unavailable.
At the same time, they would closely scrutinize the safety, transparency, and enforcement provisions to ensure compounding flexibility does not erode patient protections or allow routine substitution for regulated manufacturing.
A pragmatic moderate would view the bill as a reasonable attempt to balance patient access with safety by creating a narrowly tailored exception for urgent-use compounding during shortages while strengthening reporting requirements.
They would appreciate explicit conditions (prescriber certification, beyond-use dating, labeling, record-keeping and adverse-event reporting) but want clarity on operational details and enforcement.
Overall, they would likely support the bill if administrative burdens are manageable and FDA has the means to implement and monitor the changes.
A mainstream conservative would generally favor measures that expand timely patient access to medicines and give licensed pharmacists and physicians more flexibility to address shortages, particularly in hospitals.
However, they may be wary of additional regulatory and reporting requirements imposed on manufacturers and providers, and of any federal expansion that could create new compliance burdens.
Overall, they are likely to support the bill’s access-oriented provisions but may push to limit unnecessary regulatory complexity or unfunded mandates.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a modest, targeted regulatory adjustment addressing a recognized problem (drug shortages) and includes safeguards, which increases prospects for bipartisan support. However, the technical changes implicate FDA authority, patient safety, and commercial interests; those stakeholder frictions and moderate implementation complexity reduce the likelihood relative to purely noncontroversial technical fixes. The absence of explicit funding and the use of documentation and reporting conditions make enactment plausible but not certain.
The bill has not accumulated any surfaced votes yet.
Balance of access vs. safety: liberals emphasize stronger safety, oversight, and public reporting; conservatives emphasize preserving flexi…
On content alone, the bill is a modest, targeted regulatory adjustment addressing a recognized problem (drug shortages) and includes safegu…
Relative to its intended legislative type, this bill is a substantive statutory amendment that meaningfully revises compounding and drug‑shortage reporting law with targeted, concrete provisions, but it leaves several i…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.